Summary & Overview
CPT 0447U: aiSLE DX Flare Risk Index, SLE Biomarker Panel
CPT code 0447U designates a Proprietary Laboratory Analyses (PLA) test specific to the aiSLE® DX Flare Risk Index from Progentec Diagnostics Inc., which measures 11 plasma biomarkers by immunoassay and produces an algorithmic risk score for predicting systemic lupus erythematosus (SLE) flares. As a PLA code, 0447U is unique to a single manufacturer’s test and signals a growing portfolio of precision diagnostics that combine biomarker measurement with proprietary scoring algorithms. Nationally, PLA codes affect coverage policy development and utilization tracking because they identify discrete commercial assays rather than general test categories.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the test’s clinical purpose and service setting, payer coverage landscape at a high level, and the types of benchmarks and policy considerations typically relevant for PLA-coded diagnostics—such as coverage criteria, prior authorization trends, and reimbursement positioning. The publication also outlines clinical context for SLE flare risk assessment and what analysts and policy teams should monitor, including changes in payer medical policies, evidence requirements for clinical utility, and coding implications for laboratory billing. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 0447U is a Proprietary Laboratory Analyses (PLA) code that applies only to the aiSLE® DX Flare Risk Index test from Progentec Diagnostics Inc. The assay uses an immunoassay on a plasma specimen to measure 11 biomarkers related to systemic lupus erythematosus (SLE) and reports individual component values along with an algorithm-derived risk score indicating the patient’s likelihood of developing a clinical SLE flare.
-
Service type: Proprietary laboratory diagnostic test (PLA) using immunoassay with algorithmic risk scoring
-
Typical site of service: Clinical laboratory or commercial reference laboratory processing a plasma specimen
Clinical & Coding Specifications
Clinical Context
A 34-year-old woman with established systemic lupus erythematosus (SLE) presents for routine rheumatology follow-up after reporting increased joint pain, fatigue, and low-grade fever over the prior two weeks. Her rheumatologist considers objective risk stratification for imminent SLE flare to guide immunosuppressive adjustments. A plasma specimen is collected in the outpatient clinic (typical site of service: outpatient laboratory or clinic phlebotomy) and sent to Progentec Diagnostics for the proprietary aiSLE® DX Flare Risk Index test. The laboratory performs an immunoassay measuring 11 SLE-related biomarkers and generates component values plus an algorithm-derived risk score predicting likelihood of a clinical flare. Results are returned to the ordering rheumatologist, who incorporates the risk index alongside clinical assessment and standard labs (e.g., complement levels, anti-dsDNA, CBC) to inform monitoring intensity and timing of follow-up. Billing is submitted using PLA code 0447U for the aiSLE® DX Flare Risk Index report of the immunoassay on plasma.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (default) | Use when no special circumstances apply and service is billed normally. |
26 | Professional component | Use when billing only the professional interpretation component separate from the technical lab processing. |
TC | Technical component | Use when billing only the technical component (laboratory processing) of the test. |
52 | Reduced services | Use if the laboratory provided a reduced level of service relative to the full test (rare for PLA tests). |
53 | Discontinued procedure | Use if specimen processing was begun but testing discontinued for valid clinical or technical reasons. |
59 | Data not provided in input | Data not available in the input. |
62 | Two surgeons / dual operator (rare applicability) | Uncommonly applicable; used only if dual-qualified providers share responsibility for service components. |
78 | Return to operating room following prior procedure (not typical) | Not typically used for diagnostic lab tests; included per input modifier list for completeness when applicable. |
80 | Assistant at surgery (not typical) | Not typically applicable to lab tests; included per input list. |
QK | Medical direction of 2–4 qualified individuals | Use if a qualifying physician medically directs multiple staff performing the assay service. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 207R00000X | Rheumatology | Ordering specialists who commonly request SLE flare risk testing. |
| 363L00000X | Clinical Laboratory | Laboratories performing immunoassays and PLA testing. |
| 208D00000X | Dermatology | Dermatologists managing cutaneous lupus who may order flare risk testing. |
| 208000000X | Internal Medicine | Primary care or hospitalists who may order monitoring tests for SLE patients. |
| 261QM0800X | Pathology | Pathologists overseeing clinical laboratory testing and validation. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
M32.10 | Systemic lupus erythematosus, unspecified | Represents a general SLE diagnosis for which flare risk assessment is directly applicable. |
M32.9 | Systemic lupus erythematosus, organ or system involvement unspecified | Used when SLE is present without specified organ system; aiSLE® risk index helps predict systemic flare. |
M32.0 | Drug-induced systemic lupus erythematosus | Differentiates etiology; flare risk index may be less directly applicable but still relevant for activity monitoring. |
L93.0 | Discoid lupus erythematosus | Cutaneous lupus variant; dermatologists may use flare risk information when systemic involvement is a concern. |
M32.14 | Systemic lupus erythematosus with organ or system involvement, renal | Lupus nephritis represents high-risk organ involvement; flare risk assessment informs monitoring and management intensity. |
M05.79 | Rheumatoid arthritis with rheumatoid factor, other specified sites (used when overlapping autoimmune disease) | Patients with overlap syndromes may have complex monitoring needs; flare risk tools can contribute to assessment. |
R70.0 | Elevated erythrocyte sedimentation rate | Inflammatory marker often elevated with SLE activity; used alongside the aiSLE® index to assess flare probability. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
80061 | Lipid panel (total cholesterol, HDL, LDL, triglycerides) | Often ordered concurrently in SLE patients to assess cardiovascular risk and medication effects; not directly related to the PLA but commonly part of comprehensive monitoring. |
83036 | Hemoglobin A1c | Ordered when monitoring metabolic comorbidities or steroid effects in SLE patients; may be performed during the same outpatient visit. |
85025 | Complete blood count (CBC) with automated differential | Common baseline test in SLE care to detect cytopenias that can accompany disease activity or therapy; frequently ordered alongside flare risk testing. |
86140 | Antinuclear antibody (ANA), titer and pattern, if performed by immunoassay | ANA testing is a core immunologic assay in SLE evaluation and may be used in conjunction with specialized PLA tests. |
86039 | Antibodies to double-stranded DNA (anti-dsDNA) | Anti-dsDNA is a disease-specific marker correlated with SLE activity and commonly obtained with flare risk assessment. |
82728 | Complement C3 and C4 (if performed as part of separate assays) | Complement levels are standard markers of SLE activity and often interpreted alongside the aiSLE® risk index. |